Art. -Nr.: HY-15283

Clopidogrel

(Synonyms: Clopidogrelum)

32 Cited Publications

Kundenbewertung

Based on 32 publication(s) in Google Scholar

Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.43%
CAS. Nr.: 113665-84-2
Formel: C₁₆H₁₆ClNO₂S
Molecular Weight:321.82

Speicherung:

-20°C, stored under nitrogen, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

Clopidogrel Chemical Structure

CAS. Nr.: 113665-84-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vivo
- Clinical Trial
Chemical Information
Publications (32)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

P2Y12 Receptor

Alle P2Y Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Platelet	ED₅₀	4.13 mg/kg Compound: Clopidogrel	Anti-platelet activity against ADP-induced platelet aggregation in rat assessed as inhibition of platelet aggregation Anti-platelet activity against ADP-induced platelet aggregation in rat assessed as inhibition of platelet aggregation	[PMID: 36058469]
Platelet	IC₅₀	7.6 μM Compound: Clopidogrel	Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins at 37 degC by aggregometry Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins at 37 degC by aggregometry	10.1039/C4MD00022F

In Vivo

Clopidogrel, administered during the last three months, significantly decreases blood glucose, collagen and fibronectin expression compared to vehicle-treated diabetic mice. Clopidogrel markedly ameliorates hyperglycemia-induced renal fibrosis^[1]. The combination therapy of clopidogrel and aspirin (dual-antiplatelet therapy) has been shown to be significantly beneficial compared to aspirin monotherapy and has also shown to decrease sub-acute stent thrombosis as well as recurrent ischemic events following ACS^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 113665-84-2
Appearance Oil
Molecular Weight 321.82
Formel C₁₆H₁₆ClNO₂S
Color Colorless to light yellow
SMILES

ClC1=C(C=CC=C1)[C@H](N2CCC3=C(C2)C=CS3)C(OC)=O
Synonyms

Clopidogrelum
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, stored under nitrogen, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

Publications (32)

All Cell Imaging/StainingHistological Imaging/StainingRT-PCRWBIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

ACS Nano

Cryo-Shocked Platelet Coupled with ROS-Responsive Nanomedicine for Targeted Treatment of Thromboembolic Disease. [Abstract]

2023 Apr 11;17(7):6519-6533. PMID: 36971410
Neuron

More than microglial depletion: PLX5622 activates the hepatic constitutive androstane receptor to alter anesthesia and addiction. [Abstract]

2026 Apr 15;114(8):1419-1432.e7. PMID: 41734759
Theranostics

Platelets promote CRC by activating the C5a/C5aR1 axis via PSGL-1/JNK/STAT1 signaling in tumor-associated macrophages. [Abstract]

2023 Mar 27;13(6):2040-2056. PMID: 37064877
J Adv Res

Targeting MAD2B as a strategy for ischemic stroke therapy. [Abstract]

2024 Jul 5:S2090-1232(24)00269-8. PMID: 38972542
J Neuroinflammation

Hyperglycemia impairs microglia responding to retinal vasculopathy via enhanced norepinephrine-ADRB2 signaling. [Abstract]

2025 Dec 8. PMID: 41361454

Clopidogrel purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2025 Dec 8. [Abstract]

In vehicle-treated retinas, microglial processes rapidly converged toward the injury site within 30 min. This response was markedly suppressed by Clopidogrel (10 mg/kg, i.p.) treatment.
Int J Biol Sci

Clopidogrel Reduces Fibronectin Accumulation and Improves Diabetes-Induced Renal Fibrosis. [Abstract]

2019 Jan 1;15(1):239-252. PMID: 30662363

Clopidogrel purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2019 Jan 1;15(1):239-252. [Abstract]

Representative images of kidney tissue H&E (upper panel) and Sirius red staining (lower panel) of control (Ctl) and diabetic mice (DM) with or without Clopidogrel (20 mg/kg, p.o.) treatment (Ctl + Clo & DM + Clo).

Clopidogrel purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2019 Jan 1;15(1):239-252. [Abstract]

RT-PCR analysis of the T1D kidney tissue showed significantly elevated mRNA levels of ECM molecules, such as FN and collagen I, which were reduced by the Clopidogrel (20 mg/kg, p.o.) treatment.

Clopidogrel purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2019 Jan 1;15(1):239-252. [Abstract]

Western blot analysis confirmed that the T1D-induced increase in the FN expression at six months was decreased by the Clopidogrel (20 mg/kg, p.o.) treatment.

Clopidogrel purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2019 Jan 1;15(1):239-252. [Abstract]

The Clopidogrel (20 mg/kg, p.o.) treatment did not affect the body weight, however, it significantly decreased the blood glucose.
ACS Environ Au

Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]

2025 Aug 5;5(6):573-582. PMID: 41277996
PLoS Biol

Microglia sense fungal infections through capsular components from capillary-bound Cryptococcus neoformans via endothelial nucleotide signaling. [Abstract]

2026 Feb 6;24(2):e3003642. PMID: 41650189
Int J Mol Med

Platelet activation stimulates macrophages to enhance ulcerative colitis through PF4/CXCR3 signaling. [Abstract]

2025 May;55(5):78. PMID: 40084691
Biochem Pharmacol

Tyrphostin AG538 inhibits platelet activation and thrombosis via TREM2 agonism. [Abstract]

2025 Dec;242(Pt 3):117379. PMID: 41046073
J Ethnopharmacol

Mailuoning oral liquid ameliorates vasculitis in thromboangiitis obliterans rats via inactivating cGAS-STING-IRF3 and TLR4-MAPKs/NF-κB signaling pathways. [Abstract]

2024 Aug 22:118707. PMID: 39181282
Foods

Structural Insights on Hyp-Gly-Containing Peptides as Antiplatelet Compounds through Topomer CoMFA and CoMSIA Analysis. [Abstract]

2023 Feb 10;12(4):777. PMID: 36832851
Drug Des Devel Ther

Clopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157. [Abstract]

2020 Dec 21:14:5599-5610. PMID: 33376304
Int J Mol Sci

Rescue of Mitochondrial SIRT3 Ameliorates Ischemia-like Injury in Human Endothelial Cells. [Abstract]

2022 Aug 14;23(16):9118. PMID: 36012382
Front Pharmacol

Clopidogrel ameliorates high-fat diet-induced hepatic steatosis in mice through activation of the AMPK signaling pathway and beyond. [Abstract]

2024 Oct 23:15:1496639. PMID: 39508046
Front Pharmacol

Hsp47 Inhibitor Col003 Attenuates Collagen-Induced Platelet Activation and Cerebral Ischemic-Reperfusion Injury in Rats. [Abstract]

2022 Jan 10;12:792263. PMID: 35082674
Front Pharmacol

Berberine and Its Main Metabolite Berberrubine Inhibit Platelet Activation Through Suppressing the Class I PI3Kβ/Rasa3/Rap1 Pathway. [Abstract]

2021 Oct 8:12:734603. PMID: 34690771
ACS Omega

Purification and Characterization of Novel Collagen Peptides against Platelet Aggregation and Thrombosis from Salmo salar. [Abstract]

2020 Aug 4;5(32):19995-20003. PMID: 32832753
J Food Biochem

A novel di-peptide Met-Glu from collagen hydrolysates inhibits platelet aggregation and thrombus formation via regulation of Gq-mediated signaling. [Abstract]

2020 Sep;44(9):e13352. PMID: 32662128
iScience

The mechanisms and therapeutic potential of clopidogrel in mitigating diabetic cardiomyopathy in db/db mice. [Abstract]

2024 Feb 5;27(3):109134. PMID: 38375215
J Cell Physiol

Distinct Thromboxane A₂-Dependent Pathways Regulate Arachidonic Acid-Triggered VASP Phosphorylation at Ser239 and Ser157 in Human Platelets: Real-Time Visualization Reveals Superior Antithrombotic Efficacy by Targeting Thromboxane A₂ Signaling over Cyclooxygenase Inhibition. [Abstract]

2026 Mar;241(3):e70160. PMID: 41800570
Thromb Res

WY-14643, a novel antiplatelet and antithrombotic agent targeting the GPIbα receptor. [Abstract]

2024 Jun:238:41-51. PMID: 38669962
Thromb Res

OKL-1111, A modified cyclodextrin as a potential universal reversal agent for anticoagulants. [Abstract]

2023 Jul:227:17-24. PMID: 37207560
J Appl Physiol (1985)

Intravital assessment of precapillary pulmonary arterioles of type 1 diabetic mice shows oxidative damage and increased tone in response to NOS inhibition. [Abstract]

2021 Nov 1;131(5):1552-1564. PMID: 34590907
Clin Chim Acta

Simultaneous quantification of acetylsalicylic acid, clopidogrel, ticagrelor and their major metabolites in human plasma by liquid chromatography-tandem mass spectrometry. [Abstract]

2025 Dec 31:120816. PMID: 41482259
Neuroscience

P2Y12 receptor in trigeminal ganglion contributes to CFA-induced mechanical allodynia in mice. [Abstract]

2026 Aug 17:609:156-168. PMID: 42177012
Thromb J

Integrated proteomic and metabolomic profiling of lymph after trauma-induced hypercoagulopathy and antithrombotic therapy. [Abstract]

2024 Jul 10;22(1):59. PMID: 38987792
Open Chem

2020 Jun.
Am J Transl Res

Role of MKP-5-p38/MAPK pathway in Clopidogrel-induced gastric mucosal epithelial cells apoptosis and tight junction dysfunction. [Abstract]

2020 May 15;12(5):1741-1753. PMID: 32509173

Clopidogrel purchased from MedChemExpress. Usage Cited in: Am J Transl Res. 2020 May 15;12(5):1741-1753. [Abstract]

Expression of MKP-5 and phosphorylated p38/MAPK in Clopidogrel-treated gastric mucosal tissues and cells. Western blot analysis show MKP-5 is decreased and negatively correlated of Clopidogrel.
J Pharm Health Care Sci

Mixture of clopidogrel bisulfate and magnesium oxide tablets reduces clopidogrel dose administered through a feeding tube. [Abstract]

2021 May 4;7(1):18. PMID: 33941283
University of Colorado Denver

2024.
Res Sq

Lymphatic platelet thrombosis limits bone repair by precluding lymphatic transporting DAMPs. [Abstract]

2023 Nov 14:rs.3.rs-3474507. PMID: 38014223

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (155.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1073 mL

15.5366 mL

31.0733 mL

5 mM

0.6215 mL

3.1073 mL

6.2147 mL

10 mM

0.3107 mL

1.5537 mL

3.1073 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: 2.5 mg/mL (7.77 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Animal Administration^[1]

Mice^[1]
13-week-old C57BL/6J male mice are used throughout the study. After 1 week of acclimation, 15 mice are injected I.P. with streptozotocin (STZ) at a dosage of 55 mg/kg body weight daily for five consecutive days. Additional 15 mice as controls (Ctrl) are injected with a vehicle solution (0.1 mol/L citrate acid buffer, pH 4.3-4.5). Seven days after the last STZ administration, hyperglycemic mice (3-hour fasting blood glucose ≥250 mg/dL) are considered T1D (DM). This time point is defined as a baseline. Three months after diabetes induction, five diabetic and five control mice are sacrificed and blood and kidneys harvested. The remaining animals are divided in four groups: Normal control with vehicle (Ctrl), Normal control with Clopidogrel (Ctrl+ Clo), T1D (DM) with vehicle, and DM with Clopidogrel treatment (DM+Clo) and are treated with 20 mg/kg b.w./day Clopidogrel or with vehicle administered in their drinking water for three additional months. At the end of experiment, mice are intraperitoneally anesthetized with Avertin (tribromoethanol, 350 mg/kg) and sacrificed to collect blood and kidneys for mRNA, protein, and histological analyses^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zongyu Zheng, et al. Clopidogrel Reduces Fibronectin Accumulation and Improves Diabetes-Induced Renal Fibrosis. Int J Biol Sci. 2019 Jan. [Content Brief]

[2]. An insight into the interaction between clopidogrel and proton pump inhibitors By Shah, Bhavik S.; Parmar, Sanjay A.; Mahajan, Shailaja; Mehta, Anita A. From Current Drug Metabolism (2012), 13(2),225-235.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.1073 mL	15.5366 mL	31.0733 mL	77.6832 mL
	5 mM	0.6215 mL	3.1073 mL	6.2147 mL	15.5366 mL
	10 mM	0.3107 mL	1.5537 mL	3.1073 mL	7.7683 mL
	15 mM	0.2072 mL	1.0358 mL	2.0716 mL	5.1789 mL
	20 mM	0.1554 mL	0.7768 mL	1.5537 mL	3.8842 mL
	25 mM	0.1243 mL	0.6215 mL	1.2429 mL	3.1073 mL
	30 mM	0.1036 mL	0.5179 mL	1.0358 mL	2.5894 mL
	40 mM	0.0777 mL	0.3884 mL	0.7768 mL	1.9421 mL
	50 mM	0.0621 mL	0.3107 mL	0.6215 mL	1.5537 mL
	60 mM	0.0518 mL	0.2589 mL	0.5179 mL	1.2947 mL
	80 mM	0.0388 mL	0.1942 mL	0.3884 mL	0.9710 mL
	100 mM	0.0311 mL	0.1554 mL	0.3107 mL	0.7768 mL

Keywords

Clopidogrel

32 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Clopidogrel

GPCR/G Protein Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

Anti-Cardiovascular Disease Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Targeted Diversity Library

Rare Diseases Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Coagulation and Anti-coagulation Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Classic FDA-Approved Drug Library

Publications Citing Use of MedChemExpress (MCE) Clopidogrel

Alle P2Y Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (32)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Clopidogrel Related Classifications

HY-15283 Related Classifications